A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

Gemcitabine RT ver1

Description
Chemotherapy Protocol BLADDER CANCER GEMCITABINE RT Regimen Bladder – Gemcitabine RT Indication The treatment of muscle invasive bladder cancer WHO Performance status
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Gemcitabine-RT-ver1.pdf

Gemcitabine (21day) ver1.1

Description
Chemotherapy Protocol BLADDER GEMCITABINE (21 day) Regimen Bladder-Gemcitabine Indication Locally advanced or metastatic urothelial cancer in patients unsuitable for cisplatin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Gemcitabine-21day-ver1.1.pdf

Fluorouracil Mitomycin RT

Description
Chemotherapy Protocol BLADDER CANCER FLUOROURACIL-MITOMYCIN-RADIOTHERAPY Regimen • Bladder Cancer – Fluorouracil-Mitomycin-Radiotherapy Indication • Muscle invasive bladder cancer • WHO performance status
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Fluorouracil-Mitomycin-RT.pdf

Enzalutamide

Description
Chemotherapy Protocol PROSTATE ENZALUTAMIDE Regimen • Prostate-Enzalutamide Indication • Enzalutamide is recommended within its marketing authorisation as an option for treating metastatic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Enzalutamide.pdf

Docetaxel (30)-Prednisolone ver1.1

Description
Chemotherapy Protocol PROSTATE DOCETAXEL(30)-PREDNISOLONE Regimen Prostate-Docetaxel (30)-Prednisolone Indication Advanced castrate resistant prostate cancer Performance status 0, 1
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Docetaxel-30-Prednisolone-ver1.1.pdf

Darolutamide

Description
Chemotherapy Protocol PROSTATE CANCER DAROLUTAMIDE Regimen • Prostate - Darolutamide Indication • Darolutamide is recommended where the; - patient has a proven histological or cytological
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Darolutamide.pdf

Afatinib Ver 1

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Regimen AFATINIB NSCLC - Afatinib Indication Treatment of locally advanced or metastatic non-small
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/AfatinibVer1.pdf

Vinblastine Ver 1.1

Description
Chemotherapy Protocol LYMPHOMA VINBLASTINE Regimen Lymphoma – Vinblastine Indication Non-Hodgkin’s Lymphoma Hodgkin’s Lymphoma Toxicity Drug Vinblastine Adverse Effect Peripheral
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Vinblastine-Ver-1.1.pdf

Rituximab (weekly)

Description
Chemotherapy Protocol LYMPHOMA RITUXIMAB (weekly) Regimen Lymphoma – Rituximab (weekly) Indication CD20 positive indolent non Hodgkin’s lymphoma. Toxicity Drug Rituxumab Adverse
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-weekly.pdf

Rituximab (3 weekly)

Description
Chemotherapy Protocol LYMPHOMA RITUXIMAB (3 Weekly) Regimen Lymphoma – Rituximab (3 weekly) Indication Non Hodgkin’s Lymphoma in combination with chemotherapy Toxicity
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-3-weekly.pdf
501 to 510 of 1000
Previous … 49 50 51 52 53 … Next